SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : C3 ( CTHR ) Diamond in the rough?
CTHR 0.400+263.6%Oct 31 12:16 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Leslie S. Feinberg who wrote (16)11/17/1997 6:23:00 PM
From: glen  Read Replies (1) of 226
 
Les,

In the 9/30/97 C3 IPO Prospectus, there is no mention of how the test equipment works nor how it will be priced. On pps. 6-7,28, the following references are made: C3 "also obtains from Cree a component proprietary to Cree used in the production of (C3's) moissanite/diamond test instrument. (C3) believes that the test instrument may be important to building market acceptance of the Company's lab-created gemstones." "The test instrument relies upon a proprietary semiconductor chip the the Company obtains from Cree under a letter agreement dated February 12, 1996 which expires in 2016. The Instrument Agreement obligates the Company to purchase all of the chips used in the test instrument from Cree and gives the Company the exclusive right to purchase those chips from Cree. The Company will pay a royalty of 2 1/2% of net sales of all test instruments incorporating the Cree chip."

You can always call C3 or Cree for more details.

regards,
glen
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News